Michelle Carr, Author at BioTuesdays

Developments

FSD Pharma acquires Lucid Psycheceuticals

FSD Pharma (NASDAQ, CSE:HUGE; FRA:0K9) completed the acquisition of Lucid Psycheceuticals, a Toronto-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat mental health...

September 21, 2021

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Health Canada clears first-in-man study of OpSens guidewire

OpSens (TSX:OPS; OTCQX:OPSSF) received Health Canada’s approval to begin a first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement (TAVR). The...

September 20, 2021

Developments

PharmaJet to deliver Scancell COVID-19 DNA vaccines

Closely-held PharmaJet was selected by partner, Scancell, to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2, using the PharmaJet Tropis and PharmaJet Stratis Needle-free injection...

September 14, 2021

Developments

111, Inc. in $10-million share repurchase program

The board of Shanghai-based 111, Inc. (NASDAQ:YI) authorized a share repurchase program of up to $10-million of the company’s Class A ordinary shares in the form of American depositary shares in the next 12 months. The...

September 7, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Developments

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

Pfizer (NYSE:PFE) entered into a definitive agreement to acquire Trillium Therapeutics (NASDAQ, TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. ...

August 23, 2021

Developments

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) agreed with Calvert Labs, an Altasciences company, to design and execute exploratory studies related to Tryp’s psilocybin-for-neuropsychiatric disorders (PFN) program. The...

August 10, 2021

Developments

Altamira reports protective effects of Bentrio nasal spray against Influenza A virus

Altamira Therapeutics (NASDAQ:CYTO) announced positive outcomes from testing Bentrio for prophylactic or therapeutic use in influenza A virus infection. Bentrio is a drug-free nasal spray being developed by the...

August 6, 2021

Developments

iBio featured in Genetic Engineering & Biotechnology News

The advantages of iBio’s (NYSE American:IBIO) plant-based drug production system was featured in the Aug. 4 edition of Genetic Engineering & Biotechnology News. The article quoted Randy Maddux, COO of iBio, who...

August 5, 2021

Author - Michelle Carr

FSD Pharma acquires Lucid Psycheceuticals

Profound Medical gets recommendation from Timelo Investment

Health Canada clears first-in-man study of OpSens guidewire

PharmaJet to deliver Scancell COVID-19 DNA vaccines

111, Inc. in $10-million share repurchase program

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

Altamira reports protective effects of Bentrio nasal spray against Influenza A virus

iBio featured in Genetic Engineering & Biotechnology News

General

More